Product Information
Registration Status: ActiveSIN11858P
GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216mg/ML is approved to be sold in Singapore with effective from 2002-01-04. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN11858P.
This product contains Sodium Glycerophosphate 216mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by FRESENIUS KABI NORGE AS in NORWAY.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. The extent of this reaction is dependent on the activity of serum alkaline phosphatases.
Indication
Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition [FDA Label]. It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes.
Mechanism of Action
Sodium glycerophosphate acts as a donor of inorganic phosphate [A32667]. See [DB09413] for a description of phosphate's role in the body.
Pharmacokinetics
- Absorption
- Peak serum phosphate concentration is reached in 4h [A32667].
- Distribution
- Metabolism
- Glycerophosphate is hydrolyzed to form inorganic phosphate [A32667]. The extent of this reaction is dependent on serum alkaline phosphatase activity.
- Elimination
Active Ingredient/Synonyms
Disodium glycerol phosphate | Sodium glycerophosphate anhydrous | Sodium glycerophosphate |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.